Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ASMB Stock Forecast 2026-2027
$29.37
Current Price
$464.55M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ASMB Price Targets
+111.1%
To High Target of $62.00
+53.2%
To Median Target of $45.00
+32.8%
To Low Target of $39.00
ASMB Price Momentum
-5.0%
1 Week Change
-16.7%
1 Month Change
+102.7%
1 Year Change
-13.6%
Year-to-Date Change
-26.0%
From 52W High of $39.71
+279.0%
From 52W Low of $7.75
📊 TOP ANALYST CALLS
Did ASMB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Assembly Biosciences is one of their latest high-conviction picks.
Latest ASMB Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, ASMB has a bullish consensus with a median price target of $45.00 (ranging from $39.00 to $62.00). The overall analyst rating is N/A (N/A/10). Currently trading at $29.37, the median forecast implies a 53.2% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Vamil Divan at Guggenheim, suggesting a 32.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ASMB Analyst Ratings
4
Buy
0
Hold
0
Sell
ASMB Price Target Range
Low
$39.00
Average
$45.00
High
$62.00
Current: $29.37
Latest ASMB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ASMB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 22, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $50.00 |
| Nov 20, 2025 | Mizuho | Salim Syed | Outperform | Maintains | $40.00 |
| Oct 14, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $50.00 |
| Sep 24, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Initiates | $38.00 |
| Sep 8, 2025 | Guggenheim | Vamil Divan | Buy | Maintains | $39.00 |
| Aug 18, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Assumes | $50.00 |
| Mar 25, 2025 | Guggenheim | Vamil Divan | Buy | Initiates | $31.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Dec 27, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Sep 24, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Sep 20, 2024 | Jefferies | Dennis Ding | Buy | Upgrade | $35.00 |
| Jun 20, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Jun 13, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Neutral | Reiterates | $N/A |
| Mar 24, 2023 | HC Wainwright & Co. | Ed Arce | Neutral | Maintains | $1.50 |
| Nov 16, 2022 | Mizuho | Salim Syed | Buy | Maintains | $3.00 |
| Oct 24, 2022 | Truist Securities | Nicole Germino | Hold | Downgrade | $2.00 |
| Apr 1, 2022 | Truist Securities | Nicole Germino | Buy | Maintains | $12.00 |
| Sep 13, 2021 | HC Wainwright & Co. | Neutral | Initiates | $N/A | |
| Sep 2, 2021 | William Blair | Market Perform | Downgrade | $N/A |
Assembly Biosciences Inc. (ASMB) Competitors
The following stocks are similar to Assembly Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ASMB
Assembly Biosciences
mkt cap
464.55M
Assembly Biosciences Inc. (ASMB) Financial Data
Assembly Biosciences Inc. has a market capitalization of $464.55M with a P/E ratio of -4.4x. The company generates $37.19M in trailing twelve-month revenue with a -103.6% profit margin.
Revenue growth is +57.6% quarter-over-quarter, while maintaining an operating margin of -100.9% and return on equity of -36.9%.
Valuation Metrics
Market Cap
$464.55M
Enterprise Value
$234.75M
P/E Ratio
-4.4x
PEG Ratio
0.1x
Price/Sales
12.5x
Growth & Margins
Revenue Growth (YoY)
+57.6%
Gross Margin
N/A
Operating Margin
-100.9%
Net Margin
-103.6%
EPS Growth
+57.6%
Financial Health
Cash/Price Ratio
+50.1%
Current Ratio
4.4x
Debt/Equity
1.5x
ROE
-36.9%
ROA
-16.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Assembly Biosciences Inc. (ASMB) Business Model
About Assembly Biosciences Inc.
What They Do
Develops therapeutics for chronic hepatitis B virus.
Business Model
The company focuses on discovering and developing innovative therapeutics for chronic hepatitis B virus (HBV) infection and other viral diseases. It aims to generate revenue through the advancement of its pipeline of product candidates and by forming collaborations with research institutions and industry partners.
Additional Information
Assembly Biosciences is headquartered in South San Francisco, California, and is committed to addressing unmet medical needs in infectious diseases. Its research efforts could significantly improve patient outcomes and quality of life in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
73
CEO
Mr. Jason A. Okazaki J.D.
Country
United States
IPO Year
2010
Website
www.assemblybio.comAssembly Biosciences Inc. (ASMB) Latest News & Analysis
Latest News
Quick Summary
Gilead Sciences has licensed Assembly Biosciences' HSV helicase-primase inhibitor programs, including ABI-1179 and ABI-5366, aimed at treating recurrent genital herpes.
Why It Matters
Gilead's licensing of Assembly Bio's HSV programs could enhance its portfolio, potentially leading to new revenue streams and increased market competitiveness in antiviral treatments.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
ABI-1179 at a 50 mg weekly dose showed a 98% reduction in HSV-2 shedding, over 99% in high viral load shedding, and a 91% reduction in genital lesions, exceeding study expectations.
Why It Matters
The significant efficacy of ABI-1179 in reducing HSV-2 shedding and lesions suggests a strong market potential, potentially boosting the company's stock value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Assembly Biosciences, Inc. (ASMB) reported positive interim results from Phase 1b studies for its candidates ABI-1179 and ABI-5366 targeting recurrent genital herpes.
Why It Matters
Positive interim results for ABI-1179 and ABI-5366 could indicate potential for marketable treatments, influencing future revenue and stock performance for Assembly Biosciences.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
ABI-5366, a long-acting helicase-primase inhibitor, reported positive Phase 1b interim results, showing reduced viral shedding and genital lesions in recurrent genital herpes.
Why It Matters
Positive Phase 1b results for ABI-5366 suggest potential for effective treatment in recurrent genital herpes, which could lead to increased market interest and potential revenue for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Assembly Biosciences presented Phase 1b data for its investigational capsid assembly modulator ABI-4334 at AASLD, showing favorable safety and significant reductions in viral nucleic acids.
Why It Matters
Positive Phase 1b data for ABI-4334 indicates strong safety and efficacy, potentially boosting Assembly Biosciences' market position and attracting investor interest in its viral disease therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Assembly Biosciences, Inc. will participate in fireside chats at two upcoming investor conferences, focusing on its innovative therapeutics for serious viral diseases.
Why It Matters
Assembly Biosciences' participation in investor conferences signals potential updates on their therapeutic developments, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ASMB Stock
What is Assembly Biosciences Inc.'s (ASMB) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Assembly Biosciences Inc. (ASMB) has a median price target of $45.00. The highest price target is $62.00 and the lowest is $39.00.
Is ASMB stock a good investment in 2026?
According to current analyst ratings, ASMB has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $29.37. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ASMB stock?
Wall Street analysts predict ASMB stock could reach $45.00 in the next 12 months. This represents a 53.2% increase from the current price of $29.37. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Assembly Biosciences Inc.'s business model?
The company focuses on discovering and developing innovative therapeutics for chronic hepatitis B virus (HBV) infection and other viral diseases. It aims to generate revenue through the advancement of its pipeline of product candidates and by forming collaborations with research institutions and industry partners.
What is the highest forecasted price for ASMB Assembly Biosciences Inc.?
The highest price target for ASMB is $62.00 from at , which represents a 111.1% increase from the current price of $29.37.
What is the lowest forecasted price for ASMB Assembly Biosciences Inc.?
The lowest price target for ASMB is $39.00 from Vamil Divan at Guggenheim, which represents a 32.8% increase from the current price of $29.37.
What is the overall ASMB consensus from analysts for Assembly Biosciences Inc.?
The overall analyst consensus for ASMB is bullish. Out of 11 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are ASMB stock price projections?
Stock price projections, including those for Assembly Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 19, 2026 6:13 AM UTC